J&J makes $1B move for Firefly Bio, Carolyn Bertozzi’s twist on ADCs in KRAS fieldnews2026-06-08T14:53:00+00:00June 8th, 2026|Endpoints News|
Biopharma’s top-paid CEOs of 2025: 25 making $25M+ news2026-06-08T14:00:45+00:00June 8th, 2026|Endpoints News|
#ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shotnews2026-06-08T13:17:32+00:00June 8th, 2026|Endpoints News|
Takeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appealnews2026-06-08T11:01:03+00:00June 8th, 2026|Endpoints News|
#ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effectsnews2026-06-07T18:30:38+00:00June 7th, 2026|Endpoints News|
#ADA26: Pfizer monthly shot shows effect on obesity, diabetesnews2026-06-06T13:00:02+00:00June 6th, 2026|Endpoints News|
In Washington, biotech’s China hawks are winning the conversationnews2026-06-05T18:37:56+00:00June 5th, 2026|Endpoints News|
Otsuka touts new IgAN evidence as it seeks full approval for Voyxactnews2026-06-04T22:31:11+00:00June 4th, 2026|Endpoints News|
Mammalian hair, roof leaks: Novo Nordisk’s site in Indiana under FDA scrutiny once againnews2026-06-04T16:14:22+00:00June 4th, 2026|Endpoints News|
Lilly, Boehringer retrench in Germany on proposed health spending cutsnews2026-06-04T15:13:21+00:00June 4th, 2026|Endpoints News|
